Baird analyst Brian Skorney reiterated an Outperform rating and $112.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented: "Incrementally ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments